Pain Therapeutics: New Times, New Targets

D&MD’s new Pain Therapeutics market analysis report focuses on new advances in drug discovery and development. The report provides a background on pain, current therapies and research and development in the area. Profiles of companies with major pain programs include Abbott Laboratories, AstraZeneca, GlaxoSmithKline, GW Pharmaceuticals, Johnson & Johnson, Merck & Co., Neuromed Pharmaceuticals, Novartis, Pfizer, Vernalis, VistaGen Therapeutics, Xenome and more. In-depth interviews with industry leaders provide specific case studies from both biotech and academia that give a sense of what’s really going on in the trenches.

About the Author:

With more than 20 years technical and market consulting experience, Ken Rubenstein, principal of the Lion Consulting Group, is the author of more than 30 published market and industry research reports, and has consulted for more than 50 biotechnology companies and venture capital firms in areas ranging from opportunities assessment to product development. Dr. Rubenstein played key research and development roles for the Syva Company up to the vice president level. During 12 years with Syva, he co-invented their highly successful EMIT immunoassay technology, developed numerous products, and directed both project management and strategic planning activities. Dr. Rubenstein received his doctorate in chemistry from the University of Wisconsin, and did two years post-doctoral training in microbiology and molecular biology at the University of Pennsylvania School of Medicine.

July 1st 2006 Pages 189 Format PDF
Table of Contents
Table of Contents and Executice Summary

Price